Close Menu

NEW YORK (360Dx) – Finland-based Bone Index said Friday that it has received 510(k) clearance from the US Food and Drug Administration for a second-generation point-of-care diagnostic test for osteoporosis.  

The test, Bindex, uses ultrasound to measure the cortical bone thickness of the tibia and applies an algorithm to calculate the bone density index, an estimate of bone mineral density, at the hip.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.